Nospharma & cureGRIN Foundation Join Forces with a $25k Partnership

We are thrilled to announce a new partnership between Nospharma and the cureGRIN Foundation, marking a significant step forward in our commitment to advancing medical research for rare neurological conditions, with the goal to deliver new therapies to patents with GRIN Disorders. This collaboration unites our strengths in scientific innovation with a deep commitment to patient communities, aiming to foster new developments in the treatment of GRIN Disorders.

Our Shared Vision

At Nospharma, we believe that the path to transformative treatment solutions for rare brain disorders lies in working along side patients. Partnering with cureGRIN enables us to tap into a wealth of patient-centered insights, ensuring that our developments in biopharmaceuticals are not only innovative but also truly responsive to the needs of those they are meant to serve.

The cureGRIN Foundation has been a beacon of hope for countless individuals affected by GRIN disorders, providing access to essential information about these conditions and advocating for enhanced patient care. Their work is driven by a passion to improve the lives of patients and their families, making them an ideal partner for our mission.

Our Goal

Over the course of this partnership, Nospharma will test it’s lead therapeutic, NOS-01, as a potential treatment for cureGRIN in preclinical animal and cell models. This work will be led by our Chief Scientific Officer, Dr. Derek Bowie with funding from cureGRIN Foundation.

Working with cureGRIN, we hope to create a brighter future for all those affected by GRIN Disorders.